AREDS AMD Classification
Classifies age-related macular degeneration severity to determine eligibility for AREDS supplementation and guide monitoring intervals
- Highest activation tier
- Recommended
- How it is scored
- Scored in code; a stated value is compared only from the structured summary or a supplied value
- Scoring type
- classification
- Care settings
- Outpatient
When it activates
Scribeable activates a calculator from the encounter. The AREDS AMD Classification can activate when the transcript or pasted chart context documents any of these:
- Macular degeneration classification
- AMD severity grading
- AREDS supplement recommendation
- Drusen evaluation
- Age-related macular degeneration staging
A coded diagnosis can also activate it. ICD-10 prefixes carried by the registry: H35.30, H35.31, H35.32.
Inputs the note needs
1 input. Each is resolved from the transcript, the pasted chart context and charted labs; at this calculator’s tier a missing input is never requested, and a missing required input keeps the score out of the draft.
| Input | Type | Unit / options | Guidance |
|---|---|---|---|
| AREDS AMD category (1-4) | exam |
Scoring
Category 1: No AMD or normal aging changes — few small drusen (<63 microns). Category 2: Early AMD — multiple small drusen, few intermediate drusen (63-124 microns), or mild RPE abnormalities. Category 3: Intermediate AMD — extensive intermediate drusen, at least one large druse (>=125 microns), or geographic atrophy not involving fovea. Category 4: Advanced AMD — geographic atrophy involving the fovea (dry advanced) or choroidal neovascularization/neovascular AMD (wet advanced).
Interpretation
Category 1: No supplement needed — routine eye exams. Category 2: AREDS2 supplements not clearly beneficial — annual monitoring. Category 3: AREDS2 supplementation recommended (25% risk reduction for progression) — vitamin C 500mg, vitamin E 400IU, lutein 10mg, zeaxanthin 2mg, zinc 80mg, copper 2mg. Follow-up every 6-12 months, Amsler grid home monitoring. Category 4: Urgent anti-VEGF therapy for wet AMD; AREDS2 supplements for fellow eye. 5-year progression risk from Category 3 to 4: ~43% without supplements, ~30% with AREDS2.
Evidence
Sources carried in Scribeable's citation registry for this calculator; guideline version: AREDS 2001.
- Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implicationsAREDS (AMD Classification) 2001 · 2001 · NEI/NIH · Level I · link last verified 2026-03-28
How Scribeable handles it in the note
When an encounter activates the AREDS AMD Classification (its highest tier is recommended), Scribeable does not ask you for missing inputs. The score is computed in code from whatever inputs resolve from the transcript, the pasted chart context or charted labs; a computed value is written into the draft only when every required input already resolves.
The score is computed in code from the resolved inputs, not recalled by the language model. A stated AREDS AMD Classification value is compared against the computed one when the draft's structured summary carries it; a disagreement found there is flagged to the second drafting pass, which is instructed to correct the score and its interpretation, unless Scribeable has supplied the computed value to that pass, in which case the value the draft writes is checked against the supplied one and a detected difference is shown beside the note for you to adjudicate rather than silently rewritten.
Classified as a staging or classification system: activated strictly, because a wrong stage on the wrong patient is a documentation hazard.
See it activate on your own encounter
14 days of full Pro. No sales call.
14-day Pro trial with a card on file. $79/month starts 14 days after your trial begins unless you cancel first. Cancel any time from Settings > Billing.